Medical stocks show unusual activity, Ji'an Medical hits the daily limit and hits two consecutive limit-ups! Huabao Fund Medical ETF (512170) recovers the 10-day moving average.

On March 30, as the market consolidated, there were local fluctuations in the healthcare sector that drew attention! Jiuyan Medical hit the trading limit and achieved two consecutive boards, Yingke Medical rose over 6%, and Zhaoyan Pharmaceuticals increased over 5%. The largest healthcare ETF in the entire market (512170) rose nearly 1%, recovering the 10-day moving average, with real-time transactions of 550 million yuan!

In terms of news, Jiuyan Medical’s AI healthcare layout may bring expectations of a valuation reassessment. It is reported that the company has formed an AI team of over 30 people for its AIoT diabetes home assistant project, which is expected to launch the full version module and gray test in the second quarter. In February of this year, Jiuyan Medical, along with Alibaba and Tencent, jointly led an investment in a project called “The Dark Side of the Month” with over 700 million USD.

Regarding the CXO industry, the Zhejiang Merchant Pharmaceutical team pointed out that with the CXO industry continuously clearing out and the stock prices being relatively low, they are optimistic about the bottom investment opportunities in leading domestic CDMO enterprises and CRO companies benefiting from the recovery of domestic demand. From the analysis of financial, demand, and supply data, the fundamental turning point for CXO has already appeared and is expected to continue recovering.

It is noteworthy that the current valuation of the healthcare sector is still at a historical low. The latest PE (TTM) for the Huabao healthcare ETF (512170) is 28.71 times, which is lower than over 90% of the time in the past 10 years.

Data source: Shanghai and Shenzhen Stock Exchanges, China Securities Index Company, etc.

Notes: The ETFs mentioned in this article do not charge sales service fees. Fund rates are detailed in each fund’s legal documents. Risk warning: The constituent stocks of the indices mentioned are for display only, and the descriptions of individual stocks do not constitute any form of investment advice, nor do they represent the holdings or trading trends of any funds managed by the manager. The constituent stock composition of the target index is adjusted in a timely manner according to the index compilation rules. The risk level assessed by the fund manager for the healthcare ETF linked fund and the Hong Kong Stock Connect healthcare ETF Huabao is R4 - medium-high risk, suitable for aggressive (C4) and above investors, the risk level of the healthcare ETF is R3 - medium risk, suitable for balanced (C3) and above investors. Any information mentioned in this article (including but not limited to individual stocks, comments, predictions, charts, indicators, theories, and any form of expression) is for reference only, and investors must take responsibility for any investment decisions made independently. Additionally, any opinions, analyses, and forecasts in this article do not constitute investment advice in any form for the reader, nor do they bear any responsibility for direct or indirect losses caused by the use of the content of this article. Fund investments carry risks, the past performance of the fund does not guarantee its future performance, and the performance of other funds managed by the fund manager does not constitute a guarantee of the fund’s performance, and fund investments should be cautious.

MACD golden cross signal formed, these stocks are performing well!

Massive information and precise interpretations are available in the Sina Finance APP.

责任编辑：杨赐